ArticleAlzheimer's research & therapy2025
Post-infection brain atrophy accelerates cognitive and molecular changes underlying dementia.
Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfections have been associated with a greater risk of Alzheimer’s disease and related dementias (ADRD), but it is unclear how infections influence structural brain patterns over time, and whether post-infection brain atrophy can accelerate cognitive decline and molecular changes underlying dementia.
methodsUsing the Baltimore Longitudinal Study of Aging (BLSA; n = 793; mean age = 70.1), we examined how infections relate to longitudinal changes in machine learning-derived, 3 T-MRI neuroimaging signatures, and leveraged the UK Biobank (UKB; 1,120; mean age = 62.9 yrs) to externally validate infection-brain atrophy relationships. Using the BLSA, we also asked if infection history and infection-related brain volume loss were associated with cognitive decline, amyloid-beta PET, and ADRD plasma biomarker trajectories (Aβ42/40, pTau-181, NfL, GFAP).
resultsWe detected accelerated parieto-temporal atrophy in BLSA participants with a history of upper respiratory tract, bacterial, and urinary tract infections (p < 0.05), as well as influenza and skin/subcutaneous infections (FDR p < 0.05). After demonstrating their associations with longitudinal neuroimaging signatures in the UKB and prevalent dementia in the BLSA, we found that infections were related to a greater burden of ADRD plasma biomarkers and accelerated rates of cognitive decline in BLSA participants. Integrating longitudinal brain scans, cognitive assessments, and plasma biomarker measurements, we identified infection-related changes in verbal memory and NfL that were more prominent among BLSA participants who experienced greater post-infection brain atrophy.
conclusionAlong with demonstrating that infections mediate clinically relevant brain atrophy patterns, these findings highlight the consequences of post-infection brain volume loss on longitudinal neurocognitive outcomes and extend our understanding of the biological basis by which infections may contribute to neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.